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Abstract
Lan is a high-incidence blood group antigen expressed in more than 99.9% of the population. Identification of the human
ABC transporter ABCB6 as the molecular basis of Lan has opened the way for studies assessing the relation of ABCB6
function and expression to health and disease. To date, 34 ABCB6 sequence variants have been described in association
with reduced ABCB6 expression based on the genotyping of stored blood showing weak or no reactivity with anti-Lan
antibodies. In the present study we examined the red blood cell (RBC) surface expression of ABCB6 by quantitative flow
cytometry in a cohort of 47 healthy individuals. Sequencing of the entire coding region of the ABCB6 gene in low RBC
ABCB6 expressors identified a new allele (IVS9+1G.A, affecting a putative splice site at the boundary of exon 9) and two
nonsynonymous SNPs listed in the SNP database (R192Q (rs150221689) and G588 S (rs145526996)). The R192Q mutation
showed co-segregation with reduced RBC ABCB6 expression in a family, and we found the G588 S mutation in a compound
heterozygous individual with undetectable ABCB6 expression, suggesting that both mutations result in weak or no
expression of ABCB6 on RBCs. Analysis of the intracellular expression pattern in HeLa cells by confocal microscopy indicated
that these mutations do not compromise overall expression or the endolysosomal localization of ABCB6. Genotyping of two
large cohorts, containing 235 and 1039 unrelated volunteers, confirmed the high allele frequency of Lan-mutations. Our
results suggest that genetic variants linked to lower or absent cell surface expression of ABCB6/Langereis may be more
common than previously thought.
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Introduction
ATP-binding cassette (ABC) transporters make up one of the
largest protein families from bacteria to man [1]. ABC proteins are
essential for many physiological processes, and mutations in these
genes have been linked to several human genetic disorders
including cystic fibrosis, connective tissue mineralization, neuro-
logical disease, retinal degeneration, cholesterol and bile transport
defects, anemia and gout [2]. Human ABC transporters transport
a large variety of endogenous substrates and xenobiotic com-
pounds. Despite extensive studies, the physiological function of
several ABC transporters remains unknown.
ABC proteins are divided into seven subfamilies, based on
domain organization and sequence homology. ABCB6 belongs to
the ABCB subfamily, which includes P-glycoprotein (ABCB1/
MDR1) causing multidrug resistance of cancer cells [3]; the
TAP1/2 complex (ABCB2-3) mediating the translocation of
immunogenic peptides from the cytosol into the endoplasmic
reticulum [4]; ABCB4-MDR3 influencing the translocation of
phosphatidylcholine [5], and ABCB11 involved in the secretion of
bile acids [6].
ABCB6 is one of the four ABC transporters that were assigned
to the mitochondria. Initially, ABCB6 was reported to be a
regulator of de novo porphyrin biosynthesis by promoting the
ATP-dependent mitochondrial uptake of porphyrins [7]. Although
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e111590
initial findings suggested that loss of one Abcb6 allele in embryonic
stem (ES) cells impairs porphyrin synthesis, mice derived from
these stem cells were phenotypically normal [8]. Recent studies
have challenged the paradigm linking the function of ABCB6 to
mitochondria, and suggested that ABCB6 is localized in the
endolysosomal continuum including the plasma membrane [9],
the Golgi apparatus [10], and organelles of the vesicular system
[11,12,13,14]. ABCB6 is upregulated during erythroid differenti-
ation, and although a proportion is lost during reticulocyte
maturation through secreted exosomes, ABCB6 is expressed in
mature red blood cells at relatively high levels [15]. In 2012,
ABCB6 was revealed as the molecular basis of the Lan blood
group antigen [16]. Lan is a high frequency blood group,
expressed in more than 99.9% of most populations. Consequently,
Lan-negativity is extremely rare, estimated to appear in approx-
imately 0.005% of the Caucasian population [17]. Consistent with
the knock-out mouse study, Lan-negative individuals lack an overt
phenotype, arguing against a vital role of ABCB6 in porphyrin
synthesis. Still, the Lan antigen is medically relevant since
individuals with Lan(2) blood group may develop anti-Lan
antibodies, which can cause transfusion reactions or hemolytic
disease of the fetus or newborn.
The NCBI SNP database lists 417 ABCB6 variants/SNPs, of
which 34 have been associated with the Lan-negative phenotype.
All the Lan-negative individuals genotyped so far have inherited
two recessive null mutations. Heterozygous mutations result in
reduced erythrocytic protein levels, indicating bi-allelic expression
of ABCB6. Based on the Phase 1 publication of the 1000 Genome
genotype data [18], the global minor allele frequency (MAF) of the
Lan-associated SNPs is low, indicating that individual variations
are relatively rare. Recent studies have associated mutations in
ABCB6 with various hereditary diseases including ocular colobo-
ma [19], dominant familial pseudohyperkalemia [20] and
dyschromatosis universalis hereditaria (DUH) [21]. The patho-
physiological role of ABCB6 in these conditions is not known since
it is not possible to directly correlate sequence variations to
ABCB6 function or expression. This is partly due to the lack of our
understanding of the physiological function and the structure-
activity relationships within ABCB6, and also to the complex
regulation of protein synthesis, maturation, trafficking and
posttranslational modifications of membrane proteins.
Recently, we have characterized the quantitative expression of
the ABCG2 multidrug transporter corresponding to the Jra blood
group in human erythrocytes and have shown that pharmacolog-
ically relevant polymorphisms are associated with significantly
reduced ABCG2 protein expression [22]. Here we show that RBC
ABCB6 expression levels display a large variation in healthy
individuals, with an unexpectedly high frequency of low
expressors. Genotype screening of two large cohorts (containing
235 and 1039 unrelated volunteers) confirmed that genetic
variations underlying low surface ABCB6 expression are more
common than previously inferred based on the frequency of Lan-
negative blood type.
Methods
Probands
The ‘‘discovery cohort’’ consisted of 47 healthy, Hungarian
unrelated individuals [(12 males and 35 females; median age: 37
(26–66)]. Family members (n = 4) of 2 healthy volunteers with low
ABCB6 expression and two Lan-negative (Lan2) individuals with
a previous history of hemolytic disease of the newborn caused by
anti-Lan antibody were investigated additionally [23]. The
Hungarian genetic screening cohort consisted of 184 healthy,
unrelated first or second time Hungarian blood donors ((94 males,
90 females; median age 37 (22–76)). The Polish genetic screening
cohort included 1039 healthy, unrelated subjects (555 males, 484
females, median age 39 (19–76)). This sample was randomly
selected within the ‘‘normal Polish population’’ genetic collection
at the Biobank, Department of Molecular Biophysics, University of
Lodz. Genetic material for this collection was sampled in 2011–
2012 within the EU-funded TESTOPLEK research project. A
professional public opinion polling and survey-taking company
(SMG/KRC Poland, a Millward Brown subsidiary) was subcon-
tracted to select a cross-sectional sample of .10000 individuals
from the population at large, with representation from each
geographical region of Poland (number of samples from each
powiat/county proportional to the population of the county). The
individuals were selected from public records, visited in their
domiciles by SMG/KRC pollsters and asked to provide genetic
material (saliva, see below) and to fill out a general anthropological
and medical questionnaire. Since proband selection was random
from the overall population, the probands were not necessarily
healthy individuals, although the sample excluded hospitalized
patients and those unable to give informed consent. All subjects
gave their written informed consent to participate in the study.
This study was approved by the respective regional ethical
committees (The University Committee on Bioethics Research
(University of Lodz); Scientific and Research Ethics Committee of
the Healthcare Scientific Council of Hungary), and all procedures
were performed in accordance with the Declaration of Helsinki.
One patient’s sample was obtained through the NIH Undiag-
nosed Diseases Program (UDP) in the United States [24]. The
patient was enrolled in clinical protocol 76-HG-0238, approved by
the Institutional Review Board of the National Human Genome
Research Institute. The parents gave written, informed consent.
Genotyping
In the Hungarian cohort, genomic DNA was isolated from
EDTA anticoagulated peripheral blood by Gentra Purege Blood
Kit (Qiagen, Hamburg, Germany). Sanger sequencing of the
ABCB6 coding region and exon-intron boundaries (exons 1–19,
NCBI Reference Sequence: NT_005403.18) was performed by
Applied Biosystems 310 Genetic Analyzer (Life Technologies,
Carlsbad, USA). Screening for ABCB6 variants at R192
(rs150221689) or G588 (rs145526996) was performed by the
PCR restriction fragment length polymorphism method using SsiI
and Sau96I, respectively. Digested PCR products were size-
separated by electrophoresis on 2% agarose gels and visualized by
ethidium bromide staining. For the detection of ABCB6 R192
codon variants the primer pair for amplification of exons 1–2
(ABCB6-2 and ABCB6-4) was used according to Helias et al. [16],
while for the detection of ABCB6 G588 S variants the following
primers were used ABCB6-37 [16] and ABCB6-13R (59-
GGAGGCTGCACCATTCAATC-39).
For the Polish population study, saliva was collected into
Oragene OG-500 DNA collection/storage receptacles (DNA
Genotek, Kanata, Canada) and genomic DNA was subsequently
isolated by the MagNA Pure LC DNA Isolation Kit - Large
Volume (Roche, Basel, Switzerland) with its final concentration
normalized to 0.2 mg/ml. Screening for expected ABCB6 SNP
variants at R192, G588, R276 as well as the exon 9 boundary
splice site was performed by High Resolution Melting (HRM)
analysis of PCR products amplified and subsequently melted on a
BioRad C1000/CFX384 thermocycler. The reaction used 500 pg
genomic DNA as template, 2xGoTaq polymerase master mix
(Promega, Madison, USA) and LCGreen dye (BioFire Defence,
Salt Lake City, USA). HRM curves were interpreted using the
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Precision Melt Analysis Software from BioRad. Samples with
divergent melting curves were selected for re-amplification,
cloning and Sanger sequencing to confirm the presence of
respective SNPs.
The following primers were used for HRM analysis (all at 59uC
annealing temperature):
ABCB6-HRM-R192-F 59-GTTCAGTTTAGCCTGTGGGTG-
39
ABCB6-HRM-R192-R 59-CAAACAGCCCTCCAGAGACC-39
ABCB6-HRM-R276-F 59-CTGGGGCTCATGGGTTTG-39
ABCB6-HRM-R276-R 59-GGCACCAACACATTGAGTG-39
ABCB6-HRM-G588-F 59-TGGAGCAGGGCCCCTTC-39
ABCB6-HRM-G588-R 59-CATCGGCATAGCTGAAGTGC-39
ABCB6-HRM-IVS9-F 59-GCGCATACTTTGTCACTGAG-
CAG-39
ABCB6-HRM-IVS9-R 59-CCCACTCTCTCATCCAAGATCC-
39
Quantitative analysis of ABCB6 expression by flow
cytometry
Freshly drawn human blood (25 ml) was diluted in 4 ml of
phosphate buffered saline (PBS), the cells were centrifuged at
3,0006g for 10 min. Samples were processed within 3 hours, or
stored for a maximum of 2 days after fixation in 1% PFA for
60 min at 25uC. Antibody staining was performed for 40 min at
37uC by using the Human monoclonal anti-Lan (Clone OSK43;
IgG1k) (0.7 ml/tubes) specifically recognizing ABCB6 protein
[16], or without primary antibody (negative staining). Antibody
concentrations for ABCB6 labeling in red cells were carefully
calibrated to provide maximum labeling in a full range of protein
expression. After washing out the primary antibodies, secondary
antibodies corresponding to the IgG type and labeled with
phycoerythrin (PE) were added to the cells (Goat F(ab’)2 fragment
anti-human IgG-PE (Beckman Coulter, PNI 1626)), in 506
dilution, incubated for 30 min at 37oC, washed and resuspended
in PBS. The labeled samples were subjected to flow cytometry
(FACS); intact red cells were gated based on the forward scatter
(FSC) and side scatter (SSC) parameters. Intact cells were analyzed
for antibody staining by a FACSCalibur flow cytometer (excitation
wavelength: 488 nm (Argon ion laser) emission filters: 585/42 nm
for PE). RBC ABCB6 was measured 4 times in each individual
(Figure S1); relative ABCB6 expression was calculated by dividing
the median values obtained with the primary and secondary
antibodies with the weighted average of the median values
obtained with secondary antibody only. The weighted average
(WA) was calculated as follows: WA= (average secondary fluores-
cence of all measured samples*2+individually measured secondary
fluorescence)/3. Surface expression of ABCB6 variants expressed
in K562 cells was performed as described previously [15].
Figure 1. Erythrocytic ABCB6 expression in 47 healthy individuals. Histogram illustrating the distribution of erythrocytic ABCB6 expression
in 47 unrelated healthy individuals, as measured by a quantitative FACS assay using the OSK43 monoclonal antibody specifically recognizing a surface
epitope of ABCB6 (see Methods). The four individuals exhibiting significantly lower ABCB6 levels (below the 10th percentile) are labeled by asterisks.
doi:10.1371/journal.pone.0111590.g001
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Mutagenesis
cDNA encoding wild-type human ABCB6 (NM_005689)
bearing an HA-tag at its C-terminus [9,15] was mutated using
the QuikChange site-directed mutagenesis kit (Stratagene) using
the following primers:
Figure 2. Pedigree of a family carrying the ABCB6 R192Q mutation– co-segregation of the heterozygous mutation with reduced
erythrocytic ABCB6 expression levels. Blood samples obtained from the family members of the healthy volunteer proband carrying the R192Q
ABCB6 mutation (indicated with black arrow) were analyzed for ABCB6 expression and the presence of the mutation. The upper panel represents a
heterozygous R192Q (c.575G.A) sequence. The lower panel shows the segregation of R192Q heterozygosity (marked with green half circles and
squares for females and males, respectively) with reduced ABCB6 expression in erythrocytes (values in parentheses).
doi:10.1371/journal.pone.0111590.g002
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A B C B 6 - R 1 9 2 W - F 5 9 -
CCTGTGGGTGCTGtGGTATGTGGTCTCTGG-39
ABCB6-R192W-R 59-CCAGAGACCACATACCaCAGCACC-
CACAGG-39
ABCB6 -R 1 9 2Q - F 5 9 - CCTGTGGGTGCTGCaG -
TATGTGGTCTCTGG-39
ABCB6-R192Q-R 59-CCAGAGACCACATACtGCAGCACC-
CACAGG-39
ABCB6-G588S-F 59-CCCCTTCGCTTTCAGAAGaGCCG-
TATTGAGTTTGAG-39
ABCB6-G588S-R 59-CTCAAACTCAATACGGCtCTTCT-
GAAAGCGAAGGGG-39
Mutations were confirmed by sequencing.
Cell lines
The HA-tagged ABCB6 and its variants (ABCB6-G588S-HA,
ABCB6-R192Q-HA or ABCB6-R192W-HA, respectively) were
cloned into a pSEW lentiviral vector and stably expressed in K562
and HeLa cells by lentiviral transduction. Lentiviral particles were
produced in HEK293T cells transfected by the calcium phosphate
co-precipitation method according to manufacturer’s protocol
[25]. Viral titers of the supernatants were estimated by flow
cytometric measurement of HEK cells infected with a dilution
series of the supernatants; transduced cells were selected with
2 ug/ml puromycin for 2 weeks.
The K562 cell line (ATCC) was grown in RPMI 1640 medium
without nucleosides, supplemented with 10% (v/v) fetal bovine
serum (Invitrogen Cat.No. 10106-169) and with 2 mM glutamine,
100 units/mL penicillin, and 100 units/mL streptomycin (Invitro-
gen-Gibco, Carlsbad, CA, USA) at 37uC in humidified air/CO2
(19:1) atmosphere. The HeLa cell line (ATCC) was grown in
DMEM, supplemented with 10% (v/v) fetal bovine serum
(Invitrogen Cat.No. 10106-169) and with 2 mM glutamine, 100
units/mL penicillin, and 100 units/mL streptomycin (Invitrogen-
Gibco, Carlsbad, CA, USA) at 37uC in humidified air/CO2 (19:1)
atmosphere. Cell lines were regularly screened with the Myco-
plasm Detection Kit (Lonza), and the assays were carried out in
mycoplasma-negative cells.
Confocal Microscopy
Cells at 70%–80% confluency were gently washed with
Dulbecco’s modified phosphate-buffered saline (DPBS), fixed with
4% paraformaldehyde (PFA) in DPBS for 10 minutes at room
temperature, and permeabilized in methanol for 90 seconds at
room temperature. The samples were then blocked for 1 h at
room temperature in DPBS containing 2 mg/mL BSA (Sigma,
A7030), 1% fish gelatin from cold water fish skin (Sigma, G7765),
0.1% Triton-X 100 and 5% goat serum (Sigma, G9023). After
blocking, the cells were incubated for 1 h at room temperature
with the primary antibody diluted in blocking buffer. After
washing with DPBS, the cells were incubated for 1 hour at room
temperature with the respective Alexa Fluor-conjugated secondary
antibody diluted at 1:250 in blocking buffer. Where indicated,
DAPI was diluted in DPBS and added to the cells after the
incubation with the secondary antibody, for 10 minutes at room
temperature. Wheat Germ Agglutinin and LysoTracker were
added to living cells before the immunostaining procedure and
incubated for 10 min or 30 min at 37C, respectively. To label
cellular organelles, the following dyes and antibodies were used:
LysoTracker Red DND-99 (Invitrogen, L7528), DAPI (49,6-
diamidino-2-phenylindole, dihydrochloride, Sigma D9564), Alexa
Fluor 633 conjugate of WGA (Invitrogen, W21404), anti-COX IV
(3E11) Rabbit mAb #4850 (Cellular Localization IF Antibody
Sampler Kit, Cell Signaling, #4753), anti-Calnexin (Rabbit, Cell
Signaling, #4753), anti-ABCB6-567 [9], anti-HA. As secondary
antibodies we used Alexa Fluor 488 Goat Anti-Mouse IgG (H+L)
(Invitrogen, A11001), Alexa Fluor 594 Goat Anti-Rabbit IgG (H+
L) (Invitrogen, A11012) and Alexa Fluor 594 Goat Anti-Mouse
IgG (H+L) (Invitrogen, A11005). As isotype controls reagent grade
IgG from mouse and rabbit serum were used (Sigma). Samples
were studied with an Olympus IX-81/FV500 laser scanning
confocal microscope, using an Olympus PLAPO 606 (1.4 NA) oil
immersion objective (Olympus Europa GmbH). Dual channel
colocalization analysis was performed by the ImageJ software with
the Colocalization Threshold and Colocalization Test plugins.
Averaged Pearson’s coefficients are reported for each subcellular
marker from 5 random pictures [26,27].
Figure 3. Characterization of ABCB6 mutations responsible for the Lan- blood type. RBC membrane lysates (80 ug/lane) were prepared
from a compound heterozygote individual carrying the R276W and the G588S mutations (lane 1); homozygotes carrying the R192W mutation
(c.574C.T, p.Arg192Trp); lanes 2, 3); or individuals carrying two wild-type alleles (lanes 4, 5). ABCB6 expression is revealed by the ABCB6-567
monoclonal antibody [9], Band III is shown as loading control.
doi:10.1371/journal.pone.0111590.g003
Screening the Expression of ABCB6 in Erythrocytes
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111590
Results and Discussion
Population analysis of gene expression is typically achieved by
quantifying levels of mRNA; however, gene expression is also a
function of protein translation and turnover [28]. We used a flow
cytometry-based assay for the quantitative determination of red
blood cell ABCB6 expression in 47 unrelated, healthy individuals.
ABCB6 expression was measured with the OSK43 monoclonal
antibody specifically recognizing the Lan blood group antigen that
is carried by ABCB6 [16]. Significant ABCB6 levels, encompass-
ing a wide range of expression were detected in all but four
individuals, who showed significantly lower ABCB6 levels (below
the 10th percentile, Figure 1, Figure S1). Differences in RBC
ABCB6 expression could not be attributed to age or sex. Since
mutations in the ABCB6 gene were shown to result in the rare
Lan- blood type, which is characterized by the absence of ABCB6
in red blood cells [16], we sequenced the entire coding region of
the ABCB6 gene of the four individuals exhibiting reduced RBC
ABCB6 expression. Sequencing revealed alterations in each
subject: two unrelated subjects were heterozygous for the missense
mutation c.1762G.A, p.Gly588Ser (G588 S) encoded by the
minor allele of SNP rs145526996; one subject was heterozygous
for a mutation affecting the splice donor site of intron 9 (IVS9+
1G.A); and a fourth subject was heterozygous for the missense
mutation c.574G.A,p.Arg192Gln (R192Q) encoded by the
minor allele of SNP rs150221689. The G588 S mutation was
previously reported to be associated with lower RBC ABCB6
levels [28], the putative splice site mutation has not been
described. Mutation of arginine to tryptophan at position 192
(R192W) was shown to be a null mutation that is responsible for
the Lan-negative phenotype [28] but the presence of a glutamine
at the same position has not been linked to low RBC ABCB6
expression.
In order to clarify if a direct relationship exists between the
mutation R192Q and the RBC ABCB6 expression levels, we
obtained blood samples from the family members of the proband
carrying this mutation. We found co-segregation of the reduced
RBC ABCB6 expression and the R192Q mutation, confirming the
direct genotype-phenotype correlation (Figure 2). Segregation of
the mutation with reduced expression indicates that the missense
mutation R192Q defines a novel ABCB6 allele related to weak or
no expression of ABCB6 on RBCs.
The G588S (rs145526996) mutation was reported to result in a
significant drop in RBC ABCB6 expression in heterozygous
individuals in a previous study that also found decreased RBC
ABCB6 levels in heterozygous individuals carrying the
p.Arg276Trp mutation [28]. Our study confirms the association
of both of these mutations with reduced RBC ABCB6 levels. We
were unable to detect ABCB6 expression in the erythrocyte of a
compound heterozygote patient referred to us carrying both the
R276W and the G588S mutations (c. 826C.T, p.Arg276Trp/
c.1762G.A, p.Gly588Ser), corroborating the conclusion that
these mutations correspond to weak or no expression of ABCB6
on RBCs (Figure 3).
Next, we wanted to further analyze the apparent deleterious
effect of the mutations identified in low RBC ABCB6 expressors
using Hela cells stably expressing the wild-type or the mutant
ABCB6 proteins. Since the mutations did not compromise overall
Figure 4. Determination of the subcellular localization of ABCB6 variants. A. Double immunofluorescence labeling and laser-scanning
confocal microscopy images of HeLa cells overexpressing ABCB6-HA, ABCB6-HA-G588S, ABCB6-HA-R192Q or ABCB6-HA-R192W, probed with the
ABCB6-567 antibody (green) [9] in the context of LysoTracker (red) or Calnexin (red). B. Colocalization of ABCB6-variants with various intracellular
markers. Bars represesent averaged Pearson’s coefficients +/2 standard deviation for each subcellular marker from 5 random pictures. Blue: ABCB6-
HA; red: ABCB6-HA-G588S; green: ABCB6-HA-R192Q; purple: ABCB6-HA-R192W.
doi:10.1371/journal.pone.0111590.g004
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expression levels, we analyzed the localization of ABCB6 variants
in intracellular compartments using confocal microscopy. While
initial reports indicated localization of ABCB6 in the outer
mitochondrial membrane [7,9], more recent studies detected
ABCB6 in the plasma membrane [9], the Golgi apparatus [10],
and in organelles of the vesicular system [11,12,13,14,15]. In line
with the reports demonstrating the endolysosomal localization of
ABCB6, our HA-tagged ABCB6 construct appeared in the
lysosomal compartment of Hela cells, and not in the mitochondria
(Figure 4). As opposed to the distinct endolysosomal pattern of the
wild-type protein, the R192W variant showed ER localization,
supporting the conclusion that the R192W mutation results in the
ER-retention of the protein [28]. Although both the R192Q and
R192W mutations are predicted to be potentially damaging by the
PolyPhen-2 algorithm [29], the R192Q mutation did not change
the expression pattern of ABCB6 in Hela cells. Similarly, the
intracellular expression pattern of the G588 S variant did not
differ from that of wild-type ABCB6 (Figure 4A, B).
Low RBC ABCB6 expression may be the result of a general
folding defect, or may be linked to a yet unknown, erythrocyte-
specific trafficking event. Red blood cells undergo significant
membrane remodeling during the late stages of differentiation.
During this process proteins residing in intracellular membrane
compartments are redistributed to the plasma membrane of
mature erythrocytes. Regulation of the intracellular trafficking and
the molecular details of targeting of the ABCB6 protein are not
known. In our experiments, endogenous ABCB6 is confined to the
endolysosomal compartment in most cell lines, including the HeLa
cells used in this study. We have also shown that C-terminal tags
do not influence intracellular localization of ABCB6 [15] –still,
there are numerous reasons why epithelial HeLa cells may not be
an ideal model for membrane expression in erythrocytes.
Therefore, we turned to K562 human erythroleukemia cells that
are frequently used as a model system for erythroid cells [30].
Surface expression of the ABCB6 variants was monitored in intact
cells, using the OSK43 antibody that recognizes an extracellular
epitope (i.e., the Lan antigen) while global expression was
monitored after permeabilizing the cells. Expression of the wild-
type protein resulted in significant surface labeling, showing that
2–5% of the total protein population resides in the plasma
membrane when ABCB6 is overexpressed in K562 cells. The
R192Q and G588S mutations did not impede expression levels.
The R192W variant did not reach the plasma membrane of K562
cells, in line with its ER retention in HeLa cells (Figure 5A, B).
Disease-causing mutations of medically relevant ABC proteins
(such as ABCC7-CFTR and ABCC6) often result in deficient
folding, altered trafficking and a consequent degradation mediated
by the proteasome [31,32]. Treatment of K562 cells with the
chemical chaperone 4-phenylbutyrate (4-PBA) or the proteasome
inhibitor MG132 did not restore the expression of the R192W-
ABCB6 variant, indicating that the folding defect could not be
overcome (Figure 5C, D).
The function of ABCB6 in red blood cells is unknown. The
medical relevance of RBC ABCB6 expression is based on its
association with severe haemolytic transfusion reactions or the
mild haemolytic disease of the foetus and newborn. The Lan-
negative blood type is believed to be very rare (1:20000 random
individuals are Lan-negative) [17], and is usually identified
Figure 5. Detection of relative plasma membrane ABCB6 levels by flow cytometry. K562 cells were stably transduced with retroviral
constructs encoding wild-type (WT), or mutated ABCB6 variants (R192W, R192Q, G588S). Cell surface (A, C) and total (B, D) ABCB6 expression was
analyzed by flow cytometry using the monoclonal anti-Lan OSK43 antibody [16] in intact and permeabilized cells, respectively. The effect of
pharmacological chaperoning and the inhibition of the proteasome (C, D) was studied by culturing the cells in the presence of 2 mM 4-PBA or 0.5 uM
MG132, respectively. Bars represent average ABCB6 expression +/2 standard deviation of at least 3 independent experiments.
doi:10.1371/journal.pone.0111590.g005
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Table 1. Molecular genetics of the ABCB6 gene.
NUCLEOTIDE
CHANGE
AMINO ACID
CHANGE rs#
AF (%)
(NCBI/this study)
EFFECT OF
THE SNP SOURCE
1A.C Lan (2) blood type [41]
55A.T M19L Lan (2) blood type [41]
85_87del F29del Lan (2) blood type [28]
197_198insG A66fs Lan (2) blood type [16]
296_301insG A101fs Lan (2) blood type [42]
376delG V126fs rs377591749 N.D. Lan (2) blood type [17]
459del L154fs Lan (2) blood type [42]
574C.T R192W rs149202834 0.09/0.86 Lan (2) blood type [17] [28] this study
717G.A Q239X rs148458820 0.05 Lan (2) blood type [16]
718C.T R240X Lan (2) blood type [42]
827G.A R276Q rs200125320 N.D./0.27 Lan (2) blood type [41] this study
881_884del T294fs Lan (2) blood type [42]
953_956del G318fs Lan (2) blood type [16]
97121G.A splice variant Lan (2) blood type [41]
1236G.A W412X Lan (2) blood type [17]
1533_1543dup L515fs Lan (2) blood type [16]
1558_1559insT V520fs Lan (2) blood type [17]
1617delG G539del Lan (2) blood type [42]
1690_1691del M564fs Lan (2) blood type [16]
1709_1710del Q570fs Lan (2) blood type [16]
1825G.A V609M rs374541748 N.D. Lan (2) blood type [41]
1867delins G623fs Lan (2) blood type [16]
1912C.T R638C Lan (2) blood type [41]
1942C.T R648X rs376664522 N.D. Lan (2) blood type [16]
1985_1986del L662fs Lan (2) blood type [16] [17]
2155C.T Q719X Lan (2) blood type [41]
2256+2T.G splice variant Lan (2) blood type [16]
2351+1G.A splice variant rs150574070 N.D. Lan (2) blood type [41]
575G.A R192Q rs150221689 0.14/0.51 lower ABCB6 expression this study
826C.T R276W rs57467915 0.6/1.18 lower ABCB6 expression [17] [28] this study
1028G.A R343Q rs60322991 3.99 lower ABCB6 expression [17]
1762G.A G588S rs145526996 0.23/0.98 lower ABCB6 expression [17] [28] this study
1766G.A R589H rs483352876 N.D./0.04 this study
2216G.A R739H rs192931087 0.05 lower ABCB6 expression [17]
1578+1G.A splice variant N.D./0.04 lower ABCB6 expression this study
169G.A A57T coloboma [19]
2431C.G L811V coloboma [19]
508A.G S170G DUH [21]
964A.C S322L DUH [43]
1067T.C L356P DUH [21]
1358C.T A453V rs373246472 N.D. DUH [43]
459delC DUH [44]
1663C.A G555K DUH [44]
1736G.A G579E DUH [21]
1123C.T R375W pseudohyperkalemia [20]
1124G.A R375Q pseudohyperkalemia [20]
Abbreviations: DUH: dyschromatosis universalis hereditaria; del: deletion; dup: duplication; fs: frameshift; ins: insertion; N.D.:not determined; rs: RefSNP.
doi:10.1371/journal.pone.0111590.t001
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through the presence of anti-Lan antibodies stimulated by
transfusion or pregnancy [33]. In this study we use a quantitative
FACs assay and immunoblotting to associate genetic variations
with reduced ABCB6 expression in red blood cells. Since weak
expression of the ABCB6 protein may be sufficient to suppress the
production of anti-Lan antibodies, further serological tests, based
on the reactivity of anti-Lan containing sera, are needed to
confirm the association of these mutations with Lan-negativity or
the Lan-weak phenotype [34]. The Lan-phenotype is not screened
routinely – in view of the genetic heterogeneity and the variable
expression levels, genetic and serologic screening of the population
is challenging and may be unrealistic [17]. To date, 34 alleles have
been described in association with reduced ABCB6 expression in
erythrocytes (a complete inventory is shown in Figure 6 and
Table 1). Currently, there is no information available on the
distribution of ABCB6 expression levels across the general
population, healthy subpopulations, and disease-diagnosed indi-
viduals. Screening of our cohort revealed a surprisingly high
frequency of mutations associated with reduced ABCB6 expres-
sion. To obtain carrier frequency data, we screened remaining
individuals from the discovery cohort (n = 43) and a control cohort
of 184 Hungarian blood donors for the presence of R192Q and
G588 S mutations. Further individuals carrying the R192Q allele
were not identified (suggesting an allele frequency (AF) of
0.260.2% (1/462)). The c.1762G.A, p.Gly588Ser mutation
was present in 3 additional unrelated individuals, indicating an
AF of 1.160.5% (5/462).
In order to corroborate this finding, we analyzed a library of
genetic material from 1039 healthy Polish individuals. This
analysis (based on High Resolution Melting (HRM) screening
followed by detailed sequencing analysis of variant individuals) also
led to identification of a surprisingly high number of probands
carrying mutations at the studied alleles (Table 1). At the R192
position, our analysis established the following frequencies: for the
c.574C.T variant (p.R192W, rs149202834), we found 20
heterozygous and 1 homozygous individual, with an AF of
1.0660.22%; for the c.575G.A variant (p.R192Q, rs150221689),
we found 12 heterozygous individuals, with an AF of 0.5860.17%
(these polymorphisms are not allelomorphic as they concern
separate, adjacent nucleotides within codon 192). At the codon
276, we also identified two non-allelomorphic variants: the
c.826C.T (p.R276W, rs57467915) with 28 heterozygous and 1
homozygous individual, for an AF of 1.4060.26%; and the
c.827G.A (p.R276Q, rs200125320) with 7 heterozygous individ-
uals, with an AF of 0.3460.13%. Screening of the G588 position
yielded 20 heterozygous individuals with the c.1762G.A
(p.G588S, rs145526996) polymorphic variant, for an AF of
0.9660.21%. In the same screen, we also identified an individual
with a divergent HRM curve revealing a heterozygous carrier of a
novel, hitherto unreported polymorphic variant in an adjacent
codon: c.1766G.A (p.R589H), which we registered as
rs483352876. No carriers of the splice site mutation (IVS9+1G.
A) allele were identified in the Polish cohort. Interestingly, all 7
heterozygous carriers of the R276Q polymorphism also carried
the G588S polymorphism (presumably on the same chromosome),
suggesting a one-sided linkage between the two variants in the
Polish population, perhaps due to a founder effect. The large size
of the Polish cohort allowed us to confirm with relatively high
certainty the high allele frequencies of the variants linked to weak
or no expression of ABCB6 on RBCs.
Protein levels are heritable molecular phenotypes that exhibit
considerable variation between individuals, populations and sexes
[35]. Difference in gene expression levels is thought to be a major
determinant of phenotypic variation. However, correlation
between protein and mRNA levels is generally modest; variation
in messenger RNA expression levels is not a perfect surrogate
especially for membrane protein expression because the latter is
influenced by an array of post-transcriptional regulatory mecha-
nisms. Population proteomics is the protein-level equivalent to
population genomics, where individuals are interrogated with the
aim of cataloging common genetic variants and determining how
they are distributed among people, within populations, and among
populations in different parts of the world [36]. The quantitative
analysis of the RBC membrane proteins may provide a new
biomarker platform for this type of analysis. The red cell plasma
membrane contains more than 200 proteins, mostly with unknown
Figure 6. Topology model of ABC6 showing mutations and SNPs [39,40].
doi:10.1371/journal.pone.0111590.g006
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function in the mature erythrocyte, but with key physiological
and/or pathological roles in other cell types [37,38]. Interestingly,
the RBC membrane protein levels in many cases reflect both the
genetic alterations and the cellular regulation of the expression of
these proteins [22,38]. In the present work we show that the
analysis of the ABCB6 expression in the RBC membrane allows
the combined estimation of the expression and trafficking of this
protein to the plasma membrane, as well as the discovery of
heritable mutations related to the Lan-negative phenotype.
Supporting Information
Figure S1 RBC ABCB6 expression in 47 individuals.
(TIF)
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